1. Home
  2. VRAX vs APVO Comparison

VRAX vs APVO Comparison

Compare VRAX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • APVO
  • Stock Information
  • Founded
  • VRAX 2013
  • APVO 2016
  • Country
  • VRAX United Kingdom
  • APVO United States
  • Employees
  • VRAX N/A
  • APVO 40
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • APVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • APVO Health Care
  • Exchange
  • VRAX Nasdaq
  • APVO Nasdaq
  • Market Cap
  • VRAX 7.3M
  • APVO 5.4M
  • IPO Year
  • VRAX 2022
  • APVO N/A
  • Fundamental
  • Price
  • VRAX $1.89
  • APVO $3.73
  • Analyst Decision
  • VRAX
  • APVO Strong Buy
  • Analyst Count
  • VRAX 0
  • APVO 1
  • Target Price
  • VRAX N/A
  • APVO $296.00
  • AVG Volume (30 Days)
  • VRAX 289.0K
  • APVO 44.5K
  • Earning Date
  • VRAX 02-05-2025
  • APVO 03-04-2025
  • Dividend Yield
  • VRAX N/A
  • APVO N/A
  • EPS Growth
  • VRAX N/A
  • APVO N/A
  • EPS
  • VRAX N/A
  • APVO N/A
  • Revenue
  • VRAX $84,872.00
  • APVO N/A
  • Revenue This Year
  • VRAX $5,169.18
  • APVO N/A
  • Revenue Next Year
  • VRAX $66.97
  • APVO N/A
  • P/E Ratio
  • VRAX N/A
  • APVO N/A
  • Revenue Growth
  • VRAX 7.03
  • APVO N/A
  • 52 Week Low
  • VRAX $0.60
  • APVO $3.65
  • 52 Week High
  • VRAX $9.00
  • APVO $399.60
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 48.72
  • APVO 32.92
  • Support Level
  • VRAX $1.58
  • APVO $3.77
  • Resistance Level
  • VRAX $2.29
  • APVO $4.47
  • Average True Range (ATR)
  • VRAX 0.23
  • APVO 0.31
  • MACD
  • VRAX -0.02
  • APVO 0.03
  • Stochastic Oscillator
  • VRAX 45.95
  • APVO 1.84

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: